Daily Newsletter

14 September 2023

Daily Newsletter

14 September 2023

ICON partners with US Government for clinical trials of Covid-19 vaccines

ICON will conduct Phase IIb clinical trials for the US BARDA-selected Covid-19 vaccine candidates as part of Project NextGen.

Phalguni Deswal September 14 2023

US Biomedical Advanced Research and Development Authority (BARDA) has partnered with Ireland-based ICON to conduct clinical trials of Covid-19 vaccine candidates selected as part of "Project NextGen".

A part of the US Government’s Strategic Preparedness and Response division, BARDA has launched Project NextGen to develop Covid-19 vaccines and therapies for current and future strains. To achieve this, BARDA plans to leverage its public-private partnerships. The government has plans to invest more than $5bn in the Project NextGen programme.

In June, the European Medicines Agency (EMA) identified the need to update the Covid-19 vaccines to include the XBB Omicron variant. The US Government seconded that sentiment, and last month, BARDA partnered with Regeneron to develop a Covid-19 monoclonal antibody vaccine candidate.

ICON’s government and public health solutions team will conduct a Phase IIb active comparator clinical trial to evaluate the efficacy of the next-generation Covid-19 vaccine, selected by BARDA, compared to the currently approved/authorised vaccines. The trial is expected to enrol 10,000 volunteers over a six-month period.

Although the Covid-19 trial activity has significantly decreased in the last two years, several trials have been initiated in 2023. As per GlobalData’s clinical trial database, more than 80 trials have been initiated for Covid-19 indication in the US and over 400 trials globally this year.

GlobalData is the parent company of Clinical Trials Arena.

ICON previously partnered with Evergreen Therapeutics to develop a Covid-19 drug therapy in 2021. The Ireland-based company also has a patent engagement platform that increased patient outreach and enrolment.

ICON has previously partnered with BARDA to conduct a clinical trial for an anthrax vaccine, AV7909. The vaccine comprises Emergent BioSolutions’s Biothrax combined with an immune system stimulant or adjuvant.

Significant opportunities and risks for disease-modifying therapies (DMTs) entering the PD market

As PD therapy currently centers on symptomatic treatment, the need for DMTs is one of the greatest unmet needs. Several companies within the late-stage PD pipeline are developing drugs that target PD via novel MOAs. KOLs remain hopeful that these companies will uncover a class of drugs that works effectively to slow or modify the disease course. Targeting α-synuclein and other neurotoxic proteins is a key strategy in the late-stage pipeline for DMTs.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close